» Articles » PMID: 34944962

Osteocytic Connexin Hemichannels Modulate Oxidative Bone Microenvironment and Breast Cancer Growth

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Dec 24
PMID 34944962
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Osteocytes, the most abundant bone cell types embedded in the mineral matrix, express connexin 43 (Cx43) hemichannels that play important roles in bone remodeling and osteocyte survival. Estrogen deficiency decreases osteocytic Cx43 hemichannel activity and causes a loss in osteocytes' resistance to oxidative stress (OS). In this study, we showed that OS reduced the growth of both human (MDA-MB-231) and murine (Py8119) breast cancer cells. However, co-culturing these cells with osteocytes reduced the inhibitory effect of OS on breast cancer cells, and this effect was ablated by the inhibition of Cx43 hemichannels. Py8119 cells were intratibially implanted in the bone marrow of ovariectomized (OVX) mice to determine the role of osteocytic Cx43 hemichannels in breast cancer bone metastasis in response to OS. Two transgenic mice overexpressing dominant-negative Cx43 mutants, R76W and Δ130-136, were adopted for this study; the former inhibits gap junctions while the latter inhibits gap junctions and hemichannels. Under normal conditions, Δ130-136 mice had significantly more tumor growth in bone than that in WT and R76W mice. OVX increased tumor growth in R76W but had no significant effect on WT mice. In contrast, OVX reduced tumor growth in Δ130-136 mice. To confirm the role of OS, WT and Δ130-136 mice were administered the antioxidant N-acetyl cysteine (NAC). NAC increased tumor burden and growth in Δ130-136 mice but not in WT mice. Together, the data suggest that osteocytes and Cx43 hemichannels play pivotal roles in modulating the oxidative microenvironment and breast cancer growth in the bone.

Citing Articles

Connexin-43 in Cancer: Above and Beyond Gap Junctions!.

Paunikar S, Tamagnone L Cancers (Basel). 2025; 16(24.

PMID: 39766090 PMC: 11674308. DOI: 10.3390/cancers16244191.


Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis.

Kaur J, Adhikari M, Sabol H, Anloague A, Khan S, Kurihara N Cancer Res. 2024; 84(23):3936-3952.

PMID: 39312185 PMC: 11611663. DOI: 10.1158/0008-5472.CAN-24-0857.


Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis.

Adhikari M, Kaur J, Sabol H, Anloague A, Khan S, Kurihara N Res Sq. 2024; .

PMID: 38558984 PMC: 10980159. DOI: 10.21203/rs.3.rs-4047486/v1.


Connexin 43 in the function and homeostasis of osteocytes: a narrative review.

Ma L, Wang W, Xu G, Li H, Liu F, Shao H Ann Jt. 2024; 9:10.

PMID: 38529291 PMC: 10929443. DOI: 10.21037/aoj-23-65.


Role of the osteocyte in bone metastasis - The importance of networking.

Verbruggen S J Bone Oncol. 2024; 44:100526.

PMID: 38304485 PMC: 10831278. DOI: 10.1016/j.jbo.2024.100526.


References
1.
Zhou J, Riquelme M, Gao X, Ellies L, Sun L, Jiang J . Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene. 2014; 34(14):1831-42. PMC: 4315766. DOI: 10.1038/onc.2014.113. View

2.
Xu H, Gu S, Riquelme M, Burra S, Callaway D, Cheng H . Connexin 43 channels are essential for normal bone structure and osteocyte viability. J Bone Miner Res. 2014; 30(3):436-48. PMC: 4333056. DOI: 10.1002/jbmr.2374. View

3.
Portakal O, Ozkaya O, Erden Inal M, Bozan B, Kosan M, Sayek I . Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem. 2000; 33(4):279-84. DOI: 10.1016/s0009-9120(00)00067-9. View

4.
Loiselle A, Jiang J, Donahue H . Gap junction and hemichannel functions in osteocytes. Bone. 2012; 54(2):205-12. DOI: 10.1016/j.bone.2012.08.132. View

5.
Siller-Jackson A, Burra S, Gu S, Xia X, Bonewald L, Sprague E . Adaptation of connexin 43-hemichannel prostaglandin release to mechanical loading. J Biol Chem. 2008; 283(39):26374-82. PMC: 2546557. DOI: 10.1074/jbc.M803136200. View